MENU
+Compare
AKBA
Stock ticker: NASDAQ
AS OF
Apr 4 closing price
Price
$1.77
Change
-$0.11 (-5.85%)
Capitalization
462.38M

AKBA Akebia Therapeutics Forecast, Technical & Fundamental Analysis

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company... Show more

Industry: #Biotechnology
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for AKBA with price predictions
Apr 04, 2025

AKBA in +18.33% Uptrend, growing for three consecutive days on March 19, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where AKBA advanced for three days, in of 265 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Bearish Trend Analysis

The 10-day RSI Indicator for AKBA moved out of overbought territory on March 20, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on March 28, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on AKBA as a result. In of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for AKBA turned negative on March 26, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .

AKBA moved below its 50-day moving average on March 24, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for AKBA crossed bearishly below the 50-day moving average on April 01, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKBA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

AKBA broke above its upper Bollinger Band on March 14, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for AKBA entered a downward trend on March 13, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AKBA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (13.044). P/E Ratio (0.000) is within average values for comparable stocks, (63.096). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.822). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (2.331) is also within normal values, averaging (249.684).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKBA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

AKBA is expected to report earnings to fall 46.70% to -5 cents per share on May 12

Akebia Therapeutics AKBA Stock Earnings Reports
Q1'25
Est.
$-0.05
Q4'24
Missed
by $0.03
Q3'24
Missed
by $0.04
Q2'24
Beat
by $0.03
Q1'24
Missed
by $0.02
The last earnings report on March 13 showed earnings per share of -10 cents, missing the estimate of -7 cents. With 6.51M shares outstanding, the current market capitalization sits at 462.38M.
A.I. Advisor
published General Information

General Information

a developer of drugs for the treatment of anemia and vascular diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
245 First Street
Phone
+1 617 871-2098
Employees
167
Web
https://www.akebia.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AFVLX19.12-1.10
-5.44%
Applied Finance Select Investor
SWMCX58.06-3.60
-5.84%
Schwab ® US Mid-Cap Index
GRGVX18.90-1.18
-5.88%
Goldman Sachs U.S. Equity ESG R
DAGVX40.58-2.74
-6.33%
BNY Mellon Dynamic Value Fund A
SACEX8.61-0.83
-8.79%
Spirit of America Energy C

AKBA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with ABOS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
-5.85%
ABOS - AKBA
43%
Loosely correlated
-1.02%
ATOS - AKBA
40%
Loosely correlated
-6.44%
ADAP - AKBA
38%
Loosely correlated
-20.31%
OCGN - AKBA
38%
Loosely correlated
+3.65%
KOD - AKBA
35%
Loosely correlated
-2.08%
More

Groups containing AKBA

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
-5.85%
Pharmaceuticals
category (304 stocks)
7%
Poorly correlated
+40.04%